GSK Leaves BIO, Joining Other Major Companies in Withdrawing Membership
GlaxoSmithKline (GSK; NYSE: GSK), a leading pharmaceutical company based in the UK, has reportedly withdrawn...
UCB
J&J Files NDA for FcRn Blocker Nipocalimab, Targets Myasthenia Gravis Market
US-based Johnson & Johnson (NYSE: JNJ) has made a global first New Drug Application (NDA)...
Tonghua Golden-Horse, UCB Seek China Approvals for Alzheimer’s, Myasthenia Gravis Drugs
China’s Tonghua Golden-Horse Pharmaceutical Industry Co. Ltd. and Belgium-based UCB (FRA: UNC) are seeking marketing...
UCB Agrees to USD 680 Million Divestment of China Neurology and Allergy Business to CBC Group and Mubadala
UCB, a Belgium-based biopharmaceutical company listed on the Brussels Stock Exchange (FRA: UNC), has announced...
Joincare Pharmaceutical Initiates Phase III Study for Anti-IL-17A mAb in Plaque Psoriasis
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced the initiation of a...
NMPA Suspends UCB’s Keppra Over Labeling Issues, Prompting Recall
The National Medical Products Administration (NMPA) has suspended approval for UCB’s Keppra (levetiracetam) concentrated solution...
Sunshine Guojian’s SSGJ-608 Hits Primary Endpoint in Psoriasis Study
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...